News | PET Imaging | August 19, 2016

New PET Imaging Technique Could Improve Understanding of Depression, Drug Treatments

Japanese study uses PET tracer to non-invasively assess neuron proliferation in areas of the brain known to be particularly affected by depression

PET, depression, neurogenesis, brain imaging, RIKEN Center for Life Science Technology study

August 19, 2016 — A new non-invasive positron emission tomography (PET) technique can obtain images of neuron proliferation in an area of the brain known to be particularly affected by depression. Scientists from the RIKEN Center for Life Science Technology (CLST) in Japan used the technique to observe this process, known as neurogenesis, in the subventricular zone and subgranular zone of the hippocampal dentate gyrus.

These two areas are known to be neurogenic regions, where neural stem cells give rise to new neurons throughout our lives. Hippocampal neurogenesis is known to be associated with depression and the effect of antidepressive medication, but it is also involved in learning and memory, so scientists are keen to find techniques that can monitor cell proliferation in the region. However, the process of neurogenesis is very hard to monitor non-invasively. It is possible using magnetic resonance imaging (MRI), but with MRI the tracers do not move into the brain effectively and must be injected directly into the brain fluid, making is invasive and difficult to perform.

PET is another method that has been used. Previously, attempts have been made to use a molecule called [18F]FLT as a marker for cell proliferation in the brain in PET, but unfortunately the difference in signal strength between regions with and without cell growth was small. "We were not exactly sure why this was happening," said Tamura, "but surmised that it is because the body actively pumps the molecule out of the brain through the blood-brain barrier, using active transport mechanisms. This means that it is difficult for [18F]FLT to accumulate in the brain in sufficient concentrations to allow effective imaging."

To test whether this was the case, they tried injecting rats with a drug called probenecid, which is known to inhibit the active transport of molecules like [18F]FLT outside of the brain. They were happy to see that the strategy worked. They found clear signals of neurogenesis in the two areas of the adult brain, and these signals were significantly decreased in the hippocampal dentate gyrus of rats that had been treated with corticosterone to trigger depression. When the rats were treated with an anti-depressive selective serotonin reuptake inhibitor, the amount of cell proliferation was shown to increase, demonstrating that the drugs were countering the loss of neurogenesis caused by the corticosterone.

According to Yosky Kataoka, M.D., Ph.D., who led the research team, "This is a very interesting finding, because it has been a longtime dream to find a non-invasive test that can give objective evidence of depression and simultaneously show whether drugs are working in a given patient. We have shown that it is possible, at least in experimental animals, to use PET to show the presence of depression and the effectiveness of drugs. Since it is known that these same brain regions are involved in depression in the human brain, we would like to try this technique in the clinic and see whether it turns out to be effective in humans as well."

For more information: www.riken.jp/en

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Bracco Imaging Acquires Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers | July 01, 2019
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company...
DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...